CMVD
Conditions
Interventions
Training group:None. Simultaneous infusion of Reganol bioactive drug and gadolinium with ammonia, completing PET/MRI imaging
Validation group:None. Simultaneous infusion of Reganol bioactive drug and gadolinium with ammonia, completing PET/MRI imaging
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: ? Age 30 to 70 years old; ? No obstructive lesions with typical angina pectoris symptoms but no coronary stenosis or mild stenosis (stenosis < 50%) confirmed by coronary angiography (or coronary CTA).
Exclusion criteria
Exclusion criteria: ? Allergic to developers such as dipyridamole and adenosine; ? Systolic blood pressure < 90 mmHg (1 mmHg = 0.133 kpa), heart rate < 40 beats/min; ? Angina caused by obstructive coronary heart disease, coronary spasm, acute myocarditis, pericarditis, cardiomyopathy, myocardial bridge, and recent acute myocardial infarction; ? Acute systemic diseases or infections, severe liver and kidney dysfunction, and uncontrolled metabolic diseases; ? Pregnant and lactating women; (6) Asthma or persistent wheezing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coronary flow reserve, CFR; | — |
Countries
China
Contacts
Public ContactXuemei wang
The First Affiliated Hospital of University of Science and Technology of
Outcome results
None listed